Cancer Drug Side Effects, Interactions & Warnings

Cancer Drug Side Effects, Interactions & Warnings [the_ad id=”28610″]

What is Ayvakit (avapritinib), and what is it used for?

Brand name: Ayvakit

Generic: avapritinib

Ayvakit is a prescription medicine used to treat adults with a certain type of stomach, bowel, or esophagus cancer called gastrointestinal stromal tumor (GIST) that cannot be treated with surgery or that has spread to other parts of the body (metastatic), and that is caused by certain abnormal platelet-derived growth factor receptor alpha (PDGFRA) genes.

Your healthcare provider will perform a test to make sure that you have this abnormal PDGFRA gene and that Ayvakit is right for you.

It is not known if Ayvakit is safe and effective in children.

What are the side effects of Ayvakit?

What are the serious side effects of Ayvakit?

Ayvakit may cause serious side effects, including:

Bleeding in your brain. Serious bleeding in the brain may happen during treatment with
Ayvakit and may lead to death. Stop taking Ayvakit and tell your healthcare provider right away if you develop any symptoms such as severe headache, vomiting, drowsiness, dizziness, confusion, or severe weakness on one or more side of your body.
If you have AdvSM, your healthcare provider will check your platelet counts before and during treatment with
Ayvakit.
Cognitive effects. Cognitive side effects are common with Ayvakit and can be severe. Tell your healthcare provider if you develop any new or worsening cognitive symptoms including:
- forgetfulness
- confusion
- getting lost
- trouble thinking
- drowsiness
- trouble staying awake (somnolence)
- word finding problems
- seeing objects or hearing things that are not there (hallucinations)
- change in mood or behavior

What are the common side effects of Ayvakit?

The most common side effects of Ayvakit in people with GIST include:

The most common side effects of Ayvakit in people with AdvSM include:

fluid retention or swelling
diarrhea
nausea
tiredness
changes in certain blood tests

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with
Ayvakit if you develop certain side effects.

Ayvakit may cause fertility problems in females and may decrease sperm production in males, which may affect your ability to have a child. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of
Ayvakit.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Is Ayvakit addictive?

No information provided

What is the dosage for Ayvakit?

Patient Selection For GIST Harboring PDGFRA Exon 18 Mutations

Select patients for treatment with Ayvakit based on the presence of a
PDGFRA exon 18 mutation. An FDA-approved test for the detection of exon 18 mutations is not currently available.

Recommended Dosage For GIST Harboring PDGFRA Exon 18 Mutations

The recommended dosage of Ayvakit is 300 mg orally once daily in patients with GIST. Continue treatment until disease progression or unacceptable toxicity.

Recommended Dosage For Advanced Systemic Mastocytosis

The recommended dosage of Ayvakit is 200 mg orally once daily in patients with AdvSM. Continue treatment until disease progression or unacceptable toxicity.
Modify dosage for adverse reactions as outlined in Table 2.

Recommended Administration

Administer Ayvakit orally on an empty stomach, at least 1 hour before or
2 hours after a meal. Do not make up for a missed dose within 8 hours of the next scheduled dose. Do not repeat dose if vomiting occurs after
Ayvakit but continue with the next scheduled dose.

Dosage Modifications For Adverse Reactions

The recommended dose reductions and dosage modifications for adverse reactions are provided in Tables 1 and 2.

Table 1: Recommended Dose Reductions for Ayvakit for Adverse Reactions

Dose Reduction	GIST (starting dose 300 mg)*	AdvSM (starting dose 200 mg)**
First	200 mg once daily	100 mg once daily
Second	100 mg once daily	50 mg once daily
Third	–	25 mg once daily
* Permanently discontinue Ayvakit in patients with GIST who are unable to tolerate a dose of 100 mg once daily. ** Permanently discontinue Ayvakit in patients with AdvSM who are unable to tolerate a dose of 25 mg once daily.

Table 2: Recommended Dosage Modifications for Ayvakit for Adverse Reactions

Adverse Reaction	Severity*	Dosage Modification
Patients with GIST or AdvSM
Intracranial Hemorrhage	Any grade	Permanently discontinue Ayvakit.
Cognitive Effects	Grade 1	Continue Ayvakit at same dose or reduced dose or withhold until improvement to baseline or resolution. Resume at same dose or reduced dose.
	Grade 2 or Grade 3	Withhold Ayvakit until improvement to baseline, Grade 1, or resolution. Resume at same dose or reduced dose.
	Grade 4	Permanently discontinue Ayvakit.
Other	Grade 3 or Grade 4	Withhold Ayvakit until improvement to less than or equal to Grade 2. Resume at same dose or reduced dose, as clinically appropriate.
Patients with AdvSM
Thrombocytopenia	<50 X 10⁹/L	Interrupt Ayvakit until platelet count is > 50 X 10⁹/L, then resume at reduced dose (per Table 1). If platelet counts do not recover above 50 X 10⁹/L, consider platelet support.
*Severity as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0

Concomitant Use Of Strong Or Moderate CYP3A Inhibitors

Avoid concomitant use of Ayvakit with strong or moderate CYP3A inhibitors. If
concomitant use with a moderate CYP3A inhibitor cannot be avoided, the starting
dosage of Ayvakit is as follows:

GIST: 100 mg orally once daily
AdvSM: 50 mg orally once daily

SLIDESHOW

Skin Cancer Symptoms, Types, Images
See Slideshow

What drugs interact with Ayvakit?

Effects Of Other Drugs On Ayvakit

Strong And Moderate CYP3A Inhibitors

Coadministration of Ayvakit with a strong or moderate CYP3A inhibitor
increases avapritinib plasma concentrations, which may increase the
incidence and severity of adverse reactions of Ayvakit. Avoid
coadministration of Ayvakit with strong or moderate CYP3A inhibitors. If
coadministration of Ayvakit with a moderate CYP3A inhibitor cannot be
avoided, reduce the dose of Ayvakit.

Strong And Moderate CYP3A Inducers

Coadministration of Ayvakit with a strong or moderate CYP3A inducer
decreases avapritinib plasma concentrations, which may decrease efficacy of
Ayvakit. Avoid coadministration of Ayvakit with strong or moderate CYP3A inducers.

Ayvakit contraindications, and pregnancy and breastfeeding safety

Before taking Ayvakit, tell your healthcare provider about all of your medical conditions, including if you:

have low platelet counts
bulging or weakening of a blood vessel wall (aneurysm) or history of bleeding in your brain
history of stroke within the last year
are pregnant or plan to become pregnant. Ayvakit can cause harm to your unborn baby.
Females who are able to become pregnant:
- Your healthcare provider should do a pregnancy test before you start treatment with
  Ayvakit.
- You should use effective birth control (contraception) during treatment with
  Ayvakit and for 6 weeks after the final dose of Ayvakit. Talk to your healthcare provider about birth control methods that may be right for you.
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with
  Ayvakit.
  Males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 6 weeks after the final dose of
  Ayvakit.
are breastfeeding or plan to breastfeed. It is not known if Ayvakit passes into your breast milk. Do not breastfeed during treatment with
Ayvakit and for at least 2 weeks after the final dose of Ayvakit. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription and over-thecounter medicines, vitamins, and herbal supplements.

Ayvakit may affect the way other medicines work, and certain other medicines may affect how
Ayvakit works. Talk to your healthcare provider prior to starting a new medicine.

Medically Reviewed on 8/19/2021

References

All sections courtesy of the U.S. Food and Drug Administration

[the_ad id=”28610″]